NO973241L - Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b. - Google Patents
Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b.Info
- Publication number
- NO973241L NO973241L NO973241A NO973241A NO973241L NO 973241 L NO973241 L NO 973241L NO 973241 A NO973241 A NO 973241A NO 973241 A NO973241 A NO 973241A NO 973241 L NO973241 L NO 973241L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- hypertriglyceridemia
- hypercholesterolemia
- hyperlipidemia
- arteriosclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Foreliggende oppfinnelse til-veiebringer nye anvendelser av forbin-delser med den generelle formel (I). hvor,oguavhengig av hverandre er hydrogen, hydroksy, halogen, tri-fluormetyl, lavere alkyl, lavere aik-oksy eller (tertiært amino)(lavere alk-oksy); ogoguavhengig av hverandre er hydrogen eller lavere alkyl, eller som et farmasøytisk akseptabelt salt derav, i kombinasjon med en farma-søytisk akseptabel bærer, til fremstil-ling av et farmasøytisk preparat for behandling eller profylakse av hyper-lipoproteinemi, hypertriglyseridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for anti-koagulativ behandling.The present invention provides novel uses of compounds of general formula (I). wherein, independently of one another, are hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); and is independently hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyper-lipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anti-coagulant treatment.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK4195 | 1995-01-13 | ||
DK4395 | 1995-01-13 | ||
DK6995 | 1995-01-20 | ||
DK77795 | 1995-06-30 | ||
DK76695 | 1995-06-30 | ||
DK76795 | 1995-06-30 | ||
PCT/DK1996/000014 WO1996021443A1 (en) | 1995-01-13 | 1996-01-10 | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
NO973241L true NO973241L (en) | 1997-07-11 |
NO973241D0 NO973241D0 (en) | 1997-07-11 |
Family
ID=27545138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO973241A NO973241D0 (en) | 1995-01-13 | 1997-07-11 | Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0804189A1 (en) |
JP (1) | JPH10511961A (en) |
CN (1) | CN1168098A (en) |
AU (1) | AU4329296A (en) |
BR (1) | BR9606890A (en) |
CA (1) | CA2208859A1 (en) |
CZ (1) | CZ212397A3 (en) |
HU (1) | HUP9800521A3 (en) |
IL (1) | IL116745A (en) |
NO (1) | NO973241D0 (en) |
WO (1) | WO1996021443A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
WO1999048497A1 (en) * | 1998-03-20 | 1999-09-30 | Novo Nordisk A/S | USE OF 3,4-DIPHENYLCHROMANS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR LOWERING PLASMA LEVELS OF Lp(a) IN A HUMAN OR SUB-HUMAN PRIMATE |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
ATE532777T1 (en) | 2004-09-21 | 2011-11-15 | Marshall Edwards Inc | SUBSTITUTED CHROMEDER DERIVATIVES, MEDICATIONS AND APPLICATIONS IN THERAPY |
CA2816319C (en) | 2010-11-01 | 2020-06-30 | Marshall Edwards, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
MX368063B (en) | 2014-02-07 | 2019-09-18 | Novogen ltd | Functionalised benzopyran compounds and use thereof. |
HUE054998T2 (en) | 2015-02-02 | 2021-10-28 | Mei Pharma Inc | Combination therapies for use in the treatment of breast cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1543749A1 (en) * | 1966-02-16 | 1969-12-11 | Merck Ag E | Process for the preparation of 3,4-cis-4-aryl-isoflavans |
US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
-
1996
- 1996-01-10 EP EP96900095A patent/EP0804189A1/en not_active Withdrawn
- 1996-01-10 JP JP8521377A patent/JPH10511961A/en active Pending
- 1996-01-10 CZ CZ972123A patent/CZ212397A3/en unknown
- 1996-01-10 CN CN96191417A patent/CN1168098A/en active Pending
- 1996-01-10 AU AU43292/96A patent/AU4329296A/en not_active Abandoned
- 1996-01-10 WO PCT/DK1996/000014 patent/WO1996021443A1/en not_active Application Discontinuation
- 1996-01-10 HU HU9800521A patent/HUP9800521A3/en unknown
- 1996-01-10 BR BR9606890A patent/BR9606890A/en not_active Application Discontinuation
- 1996-01-10 CA CA002208859A patent/CA2208859A1/en not_active Abandoned
- 1996-01-12 IL IL11674596A patent/IL116745A/en not_active IP Right Cessation
-
1997
- 1997-07-11 NO NO973241A patent/NO973241D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0804189A1 (en) | 1997-11-05 |
IL116745A0 (en) | 1996-05-14 |
WO1996021443A1 (en) | 1996-07-18 |
BR9606890A (en) | 1997-10-28 |
MX9705214A (en) | 1997-10-31 |
CA2208859A1 (en) | 1996-07-18 |
CZ212397A3 (en) | 1997-11-12 |
JPH10511961A (en) | 1998-11-17 |
CN1168098A (en) | 1997-12-17 |
IL116745A (en) | 1999-12-22 |
HUP9800521A3 (en) | 1999-12-28 |
NO973241D0 (en) | 1997-07-11 |
AU4329296A (en) | 1996-07-31 |
HUP9800521A2 (en) | 1998-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT863875E (en) | NEW COMPOUNDS 4- (OXIALCOXYPHENYL) -3-OXY-PIPERIDINE FOR THE TREATMENT OF CARDIAC AND RENAL FAILURE | |
SE8902326L (en) | CARBOXAMIDE COMPOUNDS, PROCEDURES FOR THE PREPARATION OF THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
NZ325449A (en) | Naphthyl-substituted benzimidazole derivatives as anticoagulants | |
BR0215240A (en) | Calcium derivatives and their use in treating diseases | |
ATE306261T1 (en) | ANTITHROMBOTIC AGENTS | |
NO20050073L (en) | Ring-substituted diphenyllazetidinones, their preparation, their use, and drugs containing the compounds | |
YU56995A (en) | ONLY DERIVED INDOLA | |
AP9701041A0 (en) | Pyridylpyrrole compounds. | |
BR9611400A (en) | "benzoxazine antimycobic agents". | |
MX9605741A (en) | (r)-(-)-2-{n-[4-(1,1-dioxide-3-oxo-2,3-dihydro-benzisotiazole-2-yl)-buty l]-aminomethyl}-cromane crystalline chlorhydrate. | |
DK0874812T3 (en) | New 2,3,5-trimethyl-4-hydroxyanilide derivatives, their preparation and therapeutic use thereof | |
NO973241L (en) | Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or arteriosclerosis, or for anticoagulant b. | |
NO971625L (en) | Novel peptides with immunomodulatory effects | |
MX9708696A (en) | Antibacterial cephalosporins. | |
NO983178L (en) | Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms | |
DK26289D0 (en) | USE OF 1,4-DISUBSTITUTED PIPERIDINYL FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION FOR TREATING INSOMNIA | |
FI844333L (en) | 11-SUBSTITUERADE 5H, 11H-PYRROLO / 2,1-C / / 1,4 / BENZOXAZEPINER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING SOM LAEKEMEDEL. | |
DK0701449T3 (en) | Process for the preparation of an oral solid dosage form containing diclofenac | |
NO973340L (en) | Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of obesity | |
DE69132578D1 (en) | Cephem derivatives | |
ES2102295B1 (en) | NEW COMPOUNDS DERIVED FROM N-BENZOILMETIL-PIPERIDINA. | |
BR9610175A (en) | Compound preparation process of the pharmaceutical composition and use of the compound | |
NO973242L (en) | Use of 3,4-diphenylchromanes for the preparation of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiological gynecomastia | |
ATE216883T1 (en) | USE OF 4-PHENYL-3,6-DIHYDRO-2H-PYRIDYL DERIVATIVES AS NMDA RECEPTOR SUBTYPE BLOCKERS | |
SE0102058D0 (en) | New Salts II |